Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2209

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2209
---
, delay its potential commercialization or reduce
the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities
at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need
to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we fail to
enter into future collaborations or do not have sufficient funds or expertise to undertake the necessary development and commercialization
activities, we may not be able to further develop our product candidates, bring them to market and generate revenue from sales of drugs
or continue to develop our technology, and our business may be materially and adversely affected. Even if we are successful in our efforts
to establish new strategic collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain
such strategic collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product
are disappointing. Any delay in entering into new strategic collaboration agreements related to our product candidates could delay the
development and commercialization of our product candidates and reduce their competitiveness even if they reach the market.

94

Risks
Related to Our Intellectual Property

Our
success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights
and technology, and we may not be able to ensure their protection.

Our
business will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies
and our product candidates, their respective components, synthetic intermediates, formulations, combination therapies, methods used to
manufacture them and methods of treatment, as well as successfully defending these patents against third-party challenges. We currently
license or sublicense all of the intellectual property underlying our product candidates from universities and from other institutions
such as for example, Elkurt and Rhode Island Hospital, and as such do not currently and solely maintain patents regarding the intellectual
property we use. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product
candidates is dependent upon the extent to which we have rights under valid and enforceable patents that cover these activities and whether
a court would issue an injunctive remedy. If we are unable to secure and maintain patent protection for any product or technology we
develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop